Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.

  title={Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.},
  author={Rodrigo Dienstmann and Ram{\'o}n Salazar and Josep Tabernero},
  journal={American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting},
Our understanding of the genetic and nongenetic molecular alterations associated with anti-epidermal growth factor receptor (EGFR) therapy resistance in colorectal cancer (CRC) has markedly expanded in recent years. Mutations in RAS genes (KRAS/NRAS exons 2, 3, or 4) predict a lack of clinical benefit when anti-EGFR monoclonal antibodies (mAbs) are added to chemotherapy. Genetic events in additional nodes of the mitogen-activated protein kinase (MAPK)-phosphoinositide 3-kinase (PI3K) pathways… 

Figures and Tables from this paper

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment

The expanding landscape of druggable gene alterations in metastatic colorectal cancer is reviewed, including BRAF V600E and RNF43 mutations, which are now promising positive predictive markers for matched targeted therapies in CRC.

Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines

The results indicate that NEU3 overexpression can enhance EGFR activation only if EGFR is overexpressed, indicating the existence of a threshold forNEU3-mediated EGFRactivation and suggesting that a combined treatment of NEU 3- and EGFR-targeted therapies may represent a valid option for CRC patients, which must be investigated in the future.

Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts

The superior antitumor efficacy of GC1118 alone or in combination with PI3K/mTOR/AKT inhibitors shows great therapeutic potential for the treatment of KRAS-mutant mCRC with elevated ratios of high- to low-affinity EGFR ligands andPI3K-AKT pathway activation.

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

It is found that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

The ctDNA revealed high intrapatient genomic heterogeneity following anti-EGFR therapy, and Sym004 effectively targeted EGFR ECD-mutated cancer cells, but this did not translate into clinical benefit in patients with EGfr ECD mutations, likely owing to co-occurring resistance mechanisms.

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer

The advance in mechanisms of ncRNAs in regulating anti-EGFR McAbs therapy resistance in CRC is reviewed, providing insight into exploring nc RNAs as new molecular targets and prognostic markers for CRC.

Inactivation of NF1 Promotes Resistance to EGFR Inhibition in KRAS/NRAS/BRAFV600-Wild-Type Colorectal Cancer

This study suggests that further clinical validation of NF1 status as predictor of response to anti-EGFR targeting antibodies in patients with colorectal cancer with KRAS/NRAS/BRAFV600-wild-type tumors is warranted.

STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics

Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.

Tumor bulk and sidedness and tumor bulk are identified as potential predictive biomarkers of clinical response in late-line mCRC and future prospective studies of EGFR targeting should consider tumor bulk in addition to molecular profiling in the identification of populations most likely to achieve meaningful clinical benefit.

Acquired and intrinsic resistance to colorectal cancer treatment

The classical model of resistance is discussed, which focuses primarily on mechanisms involving alterations in drug metabolism, increased drug efflux, secondary mutations in drug targets, inactivation of apoptotic pathways, p53 and DNA damage repair.



Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

KRAS mutations are identified as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

The role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer is highlighted and the use of MET inhibitors in patients displaying resistance as a result of MET amplification is encouraged.

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

A striking overlap between genes that, when mutated, drive primary and secondary resistance to anti-EGFR antibodies is illuminated, highlighting how genetically distinct resistance mechanisms biochemically converge on a limited number of signaling pathways that can be therapeutic intercepted.

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner, which explains why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Examination of cellular data with patient experience improves confidence that concomitant treatment of certain lung, head and neck, or colorectal cancers with cetuximab and an anti-ERBB2 drug may prevent or delay the development of drug resistance.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Braf status, EGFR amplification, and cytoplasmic expression of PTEN were associated with outcome measures in KRAS wild-type patients treated with a cetuximab-based regimen, and subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.

Results indicate that Sym004 may be an effective targeted therapy for Ctx(R) tumors, which exhibit increased steady-state EGFR expression secondary to alterations in EGFR trafficking and degradation and retained dependence on EGFR signaling for enhanced growth potential.

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Results suggest that overexpression of TGF-α through induction of EGFR–MET interaction contributes to cetuximab resistance in colorectal cancer cells.

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

Colorectal tumors evade EGFR blockade by constitutive activation of downstream signaling effectors and through mutations affecting receptor–antibody binding through mechanisms of resistance to cetuximab, which may occur concomitantly.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  • R. AmadoM. Wolf David Chang
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy.